Showing results (1631-1640 of 1,735) with videos related to

Sort By:
Pageof 174
Nature Reviews. Clinical Oncology|March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|June 22, 2018
Recommendations on prevention and screening for breast cancer in Hong KongT H Lam, K H Wong, K Kl Chan, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|January 29, 2016
Patient assessment of diabetes care in a pay-for-performance programHerng-Chia Chiu, Hui-Min Hsieh, Yi-Chieh Lin, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|October 16, 2018
Recommendations on prevention and screening for colorectal cancer in Hong KongT H Lam, K H Wong, K Kl Chan, et al.
The Journal of Urology|October 3, 2025
The Artificial Urinary Sphincter Clinical Outcomes Trial: Primary ResultsMelissa R Kaufman, Hadley M Wood, Ryan Terlecki, et al.
Journal of Medical Genetics|November 21, 2022
UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: <i>RAD51C</i>, <i>RAD51D</i>, <i>BRIP1</i> and <i>PALB2</i>Helen Hanson, Anjana Kulkarni, Lucy Loong, et al.
Advanced Materials (Deerfield Beach, Fla.)|March 10, 2025
Electrically Tunable and Modulated Perovskite Quantum Emitters via Surface-Enhanced Landau DampingYan Liu, Jun Zhang, Evelin Csányi, et al.
The New England Journal of Medicine|October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLCCaicun Zhou, Benjamin Solomon, Herbert H Loong, et al.
Clinical Lung Cancer|February 11, 2025
CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib ProgressionWesley K Y Wong, Kevin K S Mok, Giselle P C Tsui, et al.
Lung Cancer (Amsterdam, Netherlands)|November 4, 2025
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinibAllen C C Chen, Florence S T Mok, Wesley K Y Wong, et al.
Pageof 174